5392 篇
13905 篇
477944 篇
16302 篇
11765 篇
3932 篇
6541 篇
1252 篇
75615 篇
37826 篇
12163 篇
1661 篇
2862 篇
3420 篇
641 篇
1240 篇
1973 篇
4917 篇
3875 篇
5483 篇
自身免疫性和炎症性免疫调节剂市场报告(2016-2020年)
Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020
Global autoimmune and inflammatory immunomodulators market is dominated by biologics, with over 90% share compared with small molecules. This is primarily due to the growing popularity of monoclonal antibodies (mABs) as these biologicals have a high affinity toward specific disease cells and areas that need to be treated. Although, few biologicals are already off-patent in selected regions, or patent will expire over the forecast period, we believe that the market will continue deriving support from the advent of biosimilar and the expected approvals and launches from the strong pipeline. Considering the sensitive and complex nature of biologicals, they are mostly administered in the injectable forms. To a large pool of individuals, this remains a big hurdle in treatment acceptance. To overcome this limitation, the established vendors such as Pfizer, Abbvie, and Eli Lilly are trying to launch an oral form of these biologicals in the market. Once launched, this trend will fuel the market growth exponentially and will become one of the major growth drivers over the years to come.
PART 01: Executive summary 7
Highlights 7
PART 02: Scope of the report 8
Market overview 8
Top-vendor offerings 10
PART 03: Market research methodology 11
Research methodology 11
Economic indicators 11
PART 04: Introduction 12
Key market highlights 12
PART 05: Autoimmune and inflammatory diseases 17
Rheumatoid arthritis 17
IBD 18
Top immunomodulators for rheumatoid arthritis and
IBD 19
PART 06: Pipeline portfolio 20
PART 07: Market landscape 23
Market overview 23
Market size and forecast 24
Five forces analysis 28
PART 08: Market segmentation by type of disease 29
Global rheumatoid arthritis immunomodulators market 30
Global IBD immunomodulators market 32
PART 09: Market segmentation by molecule type 36
Global autoimmune and inflammatory biologic
immunomodulators market 36
Global autoimmune and inflammatory small molecule
immunomodulators market 40
PART 10: Geographical segmentation 41
Global autoimmune and inflammatory
immunomodulators market by geography 2015-2020 41
Autoimmune and inflammatory immunomodulators
market in Americas 45
Autoimmune and inflammatory immunomodulators
market in EMEA 48
Autoimmune and inflammatory immunomodulators
market in APAC 50
PART 11: Market drivers 53
Strong adoption of TNF-alpha inhibitors and B-cell
inhibitors 53
Development of novel therapies using innovative
technologies 54
Improved diagnostic tools increase the treatment-seeking
population 55
PART 12: Impact of drivers 57
PART 13: Market challenges 58
Discontinuation of drugs under development leading to
substantial loss of revenue 58
Growing popularity of alternative treatment procedures
hinders the market growth 58
Adverse effects of the drugs 60
PART 14: Impact of drivers and challenges 62
PART 15: Market trends 63
Emergence of oral agents likely to improve patient
outcomes 63
Advent of biosimilars expected to improve the treatment
rates 64
Focus on regenerative medicines 65
Strategic alliances and acquisitions 66
PART 16: Vendor landscape 68
Competitive scenario 68
Other prominent vendors 72
PART 17: Key vendor analysis 76
AbbVie 76
Johnson & Johnson 79
Amgen 84
F. Hoffmann-La Roche 86
Pfizer 90
PART 18: Appendix 95
List of abbreviations 95
PART 19: Explore Technavio 97